Michael W. Fried, MD is Professor of Medicine and Director of Hepatology at the University of North Carolina at Chapel Hill. Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.
From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous phase I, II, and III clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for more than 15 years as principal investigator on multiple NIH cooperative clinical trials, including as current co-Chair of the Hepatitis B Research Network (NIDDK).
Dr. Fried is the recipient of an NIH career development award, which allows him to provide mentorship to junior investigators in hepatitis research. Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network of investigators to study the real-world experience with therapies for hepatitis C.
Dr. Fried is the primary author or co-author on over 140 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. His manuscript on therapy of HCV, published in 2002, established the standard of care for this disease for more than a decade and was one of the most highly cited publications in the field of gastroenterology.
Dr. Fried was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators. Dr. Fried was recently elected to the Governing Board of the American Association for the Study of Liver Diseases (AASLD) and will assume the role of President of AASLD in 2019.